LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
|
|
- Austen Baker
- 8 years ago
- Views:
Transcription
1 LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
2 MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB Group) and BioLaunch (Sanofi) capabilities in the field of contract and manufacturing services. The platform is supported by a collaboration agreement between Sanofi* and the LFB Group** to capitalize on the use of their respective industrial capacities and to provide the widest range of CMO services to customers in the most flexible manner. MAbLaunch TM has developed considerable expertise in process and manufacturing of monoclonal antibodies and recombinant proteins using mammalian cell technology. The MAbLaunch TM offer starts with cell line, going through process and scale up and continuing into manufacturing of clinical and commercial batches. *through its subsidiary Sanofi Chimie **through its subsidiary LFB Biotechnologies Pilot facilities: Process, pilot production and scale-up Bioengineering laboratory Mammalian cell line platforms ( CHO and YB2/0 - EMABling ) Quality Control laboratory Roller bottle systems Spinners 25L Wave system 40L stainless steel bioreactor 50L & 200L disposable bioreactors Chromatography systems Virus inactivation and nanofiltration Filtration, ultrafiltration Analytical systems GMP production facilities: USP: 6 independent bioproduction lines with the following bioreactor capacities: > 1x 300L (stainless steel bioreactor) > 1x 1,000L (disposable bioreactor) > 1x 2,000L (disposable bioreactor; available soon > 3x 10,000L (stainless steel bioreactors) Industrial chromatography systems Ultrafiltration/Diafiltration systems Viral inactivation/nanofiltration Fill and finish facilities: > Pre-filled syringes from 0.5mL to 20mL > Cartridges from 1.7mL to 3.2mL > Vials from 2mL to 150mL > Lyophilized vials from 2mL to 20mL > Dosing system: time/pressure or peristaltic pump Inspection: automated or semi-automated
3 Contract Biomanufac Service Discovery Pre-clinical Clinical Registration Commercialization Expression vector construction MAb chimerization and humanization Cell line Vector transfection and transient expression Stable cell line generation and clone selection EMABling technology (see details on the right page ) Cell banking Project management Quality assurance Regulatory support Process and scale-up Cell culture Process - Media optimization, yield improvement Downstream Process Viral clearance validation Manufacturing of non-gmp batches up to 200L Analytical stability studies - QC testing GMP master and working cell bank production Manufacturing of GMP batches at 300L and 1,000L scale Manufacturing of clinical and commercial batches Manufacturing of GMP batches at 10,000L scale Galenic form Fill and finish vials, pre-filled syringes, freeze-dried vials, cartridges Stability studies Clinical packing
4 turing Services offer Cell line MAbLaunch TM is able to offer bioproduction services using the client s own cell line, or through a specific cell line program, to express the client s recombinant protein, using proprietary or non-proprietary cell expression systems. The different steps may include molecular and cellular engineering to create a chimeric or humanized monoclonal antibody by vector construction, gene transfection and cell line in order to establish a stable cell line. NEW! EMABling technology EMABling is a technology developed by the LFB Group to produce highy active recombinant monoclonal antibodies using the YB2/0 cell line. These antibodies display an enhanced antibody-dependent cellular cytotoxicity (ADCC) activity due to an improved glycosylation profile. LFB s research in this area has been based on the study of structure-function relationships for monoclonal antibodies and critical impact of post-translational modifications to their functional activity (role of glycans). Combined with specifically optimized expression vectors / CD medium and a powerful CLD process (including the use ClonePix-FL cloning robot), the EMABling platform leads to gram-per-liter producing clones. Customers now can access to the EMABling platform to produce their own recombinant high-adcc mabs. Process Development and scale-up Process and scale-up are essential to obtain a competitive commercial product. To tackle this important issue, MAbLaunch TM s services cover adaptation of cell culture to serum-free media and/or media optimization for yield improvement. Upstream and downstream process optimizations are executed in state-of-the-art facilities. MAbLaunch TM s technological options include static or stirred vessels, hollow-fiber bioreactors or disposable bioreactors. Our in-house scientists and our network of experts will facilitate the of optimum cell culture conditions for each cell line. Our engineering staff have vast experience and the technical knowledge necessary to select the best chromatography and filtration systems, most appropriate buffers to establish optimal purification processes and viral clearance methods. MAbLaunch TM has a proven track record in tackling a number of challenging processes and scale-up, resulting in successful production of many antibodies and recombinant proteins. Manufacturing of clinical and commercial batches With its versatile range of production technologies, MAbLaunch TM can undertake GMP cell banking and production of biopharmaceuticals for Phase I to Phase III clinical trials and small to large-scale commercial supplies to meet the specific needs of our customers. In conjunction with these drug substance manufacturing capabilities, MAbLaunch TM (via the international network of Sanofi facilities) is able to offer access to significant fill & finish capacities for various finished dosage forms: pre-filled syringes liquid vials lyophilized vials cartridges From state-of-the-art facilities, MabLaunch TM will be in a position to supply clinical and commercial products on a worldwide basis. According to customer needs, associated services may range from standard transfer activities (scaling-up, analytical transfer, stability studies ) to specific support on technical issues, such as dosage form switch or compatibility studies, by experienced industrial and pharmaceutical teams.
5 MAbLaunch TM is your CMO Partner for biologics Key benefits : The advantages of large pharma combined with flexible CMO services Comprehensive and global offer of services for protein-based biopharmaceuticals, from mammalian cell line to optimization of cell culture conditions and process at small scale to preclinical, clinical and commercial manufacturing of drug substance and drug product An integrated, dual platform approach, which is fully adaptable to customer needs, offering the most suitable solution for each project, from small to large production quantities Extensive experience in evaluation, optimization and scale-up; avoiding unnecessary costs and delays in Successful production track records for pre-clinical, clinical and commercial supply to biopharmaceutical companies Seamless integration: unified project management and quality assurance systems Thorough regulatory and QA support, including full documentation and controls at all steps of and manufacturing Optimized entry cost and long-term cost effectiveness management Program management and regulatory support MAbLaunch TM understands the need to be at the forefront of s in the field of Quality Assurance and Regulatory Affairs as well as the importance of transferring this information to its clients. MAbLaunch TM has access to the expertise and experience of the Sanofi and LFB teams, in Quality Control, Quality Assurance, Regulatory and Program Management. Our quality systems are dedicated to providing high-value products and services which enable our customers to conduct a project with confidence. Each project is managed by a dedicated, experienced and multidisciplinary team who works in close collaboration with each customer to ensure that milestones are reached and that cost and timeline targets are met.
6 July 2013 Design and layout: PASAYA - Photographs: LFB & Sanofi, X LFB Biomanufacturing site Impasse des Chênes Rouges Alès cedex - France About LFB Group/ LFB Biomanufacturing LFB Group is a biopharmaceutical company, and the n 1 biotech French company. LFB Group is ranked as the fifth largest plasma-derived products player worldwide, and the third largest pharma company supplying drugs to hospitals in France. In the biotechnology field, LFB Group is developing monoclonal antibodies and a line of recombinant proteins using transgenic technology with GTC BioTherapeutics, a US based company. Founded in 1997, LFB Biomanufacturing is a fully integrated contract manufacturing organization based in Alès (southern France), specializing in GMP production of recombinant proteins and monoclonal antibodies using mammalian cell-based expression systems. Contacts MAbLaunch TM Sanofi site 9 Quai Jules Guesde Vitry sur Seine - France About Sanofi/BioLaunch Sanofi, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. BioLaunch building, Jacob Development & Jacob Production, is a major operation for Sanofi in France. An investment of nearly 200 million euros will give rise to the first cell culture biotechnology platform of the Group to produce monoclonal antibodies starting in This project is a core part of the conversion plan for the Vitry-sur-Seine site turning it into a comprehensive biotechnology platform that includes research, and production activities. Furthermore, Sanofi has decided to open this platform to other companies, on the basis of their or production needs. Patrick Haddad haddadp@lfb.fr Roland BELIARD beliard@lfb.fr Global: Philippe CLAVEL philippe.clavel@sanofi.com Europe: Arnaud Martin arnaud.martin@sanofi.com North America: John FULMER john.fulmer@sanofi.com Japan: Hikaru OHSAWA hikaru.ohsawa@sanofi.com
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationBIOTECH MANUFACTURING SOLUTIONS 4 YOUR SUCCESS. a Novartis company
a Novartis company BIOTECH MANUFACTURING Sandoz GmbH Biotech Cooperations 6250 Kundl Austria Biochemiestrasse10 Phone +43 (0)5338 200 2609 Fax +43 (0)5338 200 442 biotech.cooperations@sandoz.com www.sandoz.com
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationBioprocessing Media and Buffers Grow with Us
Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationFrom cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering
From cells to therapeuticsvivalis Humalex Fully human antibody discovery platform An integrated therapeutic development offering Humalex from bench-top to clinical development The Humalex platform enables
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationHow To Develop A Cell Line
Advances in The Development of Biopharmaceuticals The application of modern technologies and services to the development of Biopharmaceutical processes Dr Jonathan H Dempsey Process Science Fellow Invitrogen
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationPharma & Biotech processes: global turnkey solutions
Pharma & Biotech processes: global turnkey solutions 02 Our mission: to design and build turnkey process solutions AS A LEADING-EDGE INDUSTRIAL INTEGRA- TOR, BOCCARD DESIGNS AND BUILDS UNIQUE PHARMACEUTICAL
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationTable of Contents. Presented by
Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com
More informationCell Discovery 360: Explore more possibilities.
Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle
More informationFacility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study
24 th Interphex, Japan, Technical Conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study Lonza AG Financially
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationImproving GS-CHO Cell Line Selection: Reducing Time to Clinic
Cell Line Development and Engineering 2-6 March 2009, Berlin Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Adrian Haines, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters
More informationGenes to Proteins to Antibodies
Genes to Proteins to Antibodies About Us Fusion Antibodies is a CRO established in 2001 as a spin-out from Queen s University Belfast. The company building is situated in a charming area of Springbank
More informationDedicated Project Management
Peptides Dedicated Project Management At Lonza, we are committed to our customers success, so it is our mission to help your product reach its full potential. We pride ourselves on delivering high-quality,
More informationTechnologies for Monoclonal Antibody Production
Technologies for Monoclonal Antibody Production First we help you bridge the distance between upstream and downstream. Then we help you shorten it. Monoclonal antibodies for therapeutic, diagnostic and
More informationIntegrated Protein Services
Integrated Protein Services Custom protein expression & purification Version DC04-0012 Expression strategy The first step in the recombinant protein generation process is to design an appropriate expression
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationProviding Trusted and Innovative Solutions t o the Life Science Communities
Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development
More informationOverview of Upstream and Downstream Processing of Biopharmaceuticals
Overview of Upstream and Downstream Processing of Biopharmaceuticals Ian Marison Professor of Bioprocess Engineering and Head of School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
More informationPharmaceuticals Production Services Boehringer Ingelheim. Our expertise in world-class contract manufacturing for your success
Pharmaceuticals Production Services Boehringer Ingelheim Our expertise in world-class contract manufacturing for your success Successful partnership Dr Wolfram Carius Head of Corporate Division Pharmaceuticals
More informationBiopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture?
BIOPHARM ROUNDTABLE Biopharm Roundtable Morrey Atkinson Vice President, R&D Cook Pharmica Peter Soelkner Managing Director Vetter Pharma-Fertigung GmbH & Co. KG Johannes Reiter Cooperations Manager Sandoz
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationMAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
More informationIntegrated Protein Services
Integrated Protein Services Custom protein expression & purification Last date of revision June 2015 Version DC04-0013 www.iba-lifesciences.com Expression strategy The first step in the recombinant protein
More informationTHE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS Table of Contents CHAPTER 1: Overview of Monoclonal Antibody Therapeutics CHAPTER 2: Monoclonal Antibody Discovery Technologies CHAPTER 3: CMC
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationAdvanced BioDesign Outlines Solutions. Antibody Overview. by Advanced BioDesign. Project Start. Immunogenicity. Selecting Your Antigen
Advanced BioDesign Outlines Solutions by Advanced BioDesign Antibody Overview Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, you may develop
More informationOne of the greatest challenges facing biopharmaceutical
Monoclonal Antibody Manufacturing Strategies for the 21st Century James Blackwell, Ph.D., MBA Sr. Consultant Thomas Ransohoff, VP and Sr. Consultant Howard L. Levine, Ph.D., President and Principal Consultant
More informationUna nueva plataforma para la producción de vectores lentivirales para preclínica y bajo cgmp
Una nueva plataforma para la producción de vectores lentivirales para preclínica y bajo cgmp XLVIII LECCIÓN CONMEMORATIVA JIMÉNEZ DÍAZ Madrid Mayo 2016 Juan C Ramírez CSO/CTO Non-Disclosure/Confidentiality
More informationMab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.
Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation. Summary Monoclonal antibodies are expensive to develop and to manufacture.
More informationNational Institute for Bioprocessing Research and Training (NIBRT)
NIBRT Catalogue 2013 2012 Training Education Training and Education Catalogue National Institute for Bioprocessing Research and Training (NIBRT) www.nibrt.ie Contents Welcome letter 1 Open courses... 3
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationLiquids Suspensions Gels
Liquids Suspensions Gels EMCM: your product development and manufacturing partner Centre of excellence European Medical Contract Manufacturing (EMCM) is the centre of excellence in developing and manufacturing
More informationCUSTOMER ORIENTED TOLL MANUFACTURING TAILORED SERVICES INTERACTIVE PROJECT MANAGEMENT CUSTOM SYNTHESIS & API CONTRACT MANUFACTURING
CUSTOMER ORIENTED TOLL MANUFACTURING TAILORED SERVICES INTERACTIVE PROJECT MANAGEMENT CUSTOM SYNTHESIS & API CONTRACT MANUFACTURING CEPiA Within the Industrial Affairs Division of Sanofi, CEPiA (Commercial
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher
ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES Dr Andrew Racher Lonza Biologics plc, 2004 Structure of talk Issues Selection of a high producing cell line Selection for process compatibility
More informationLABELMANAGEMENT WITH SAP - INTEGRATION
LABELMANAGEMENT WITH SAP - INTEGRATION Vetter Pharma-Fertigung GmbH & Co. KG LABELING SOLUTIONS FOR PROFESSIONALS SAP Labelmanagement from OPAL and BarTender label software from Seagull Scientific ensure
More informationUse of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development
Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Authors: Dr Fern Slingsby and Dr Simon Dewar Upstream Process Development FUJIFILM
More informationThe authors: Howard L. Levine, Ph.D., President and Founder. Thomas C. Ransohoff, Senior Consultant
The authors: Howard L. Levine, Ph.D., President and Founder Dr. Levine has over 20 years of experience in the biopharmaceutical industry. Prior to founding BioProcess Technology Consultants to provide
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationAccelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches
Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches 2008 IBC Formulation Strategies for Protein Therapeutics Tim Kelly, Ph.D.
More informationSingle-use bioprocessing
FOCUS ON... DISPOSABLES Upstream Single-Use Bioprocessing Systems Future Market Trends and Growth Assessment by Ronald A. Rader and Eric S. Langer Single-use bioprocessing equipment has become wellaccepted
More informationCustom Antibodies & Recombinant Proteins
Custom Antibodies & Recombinant Proteins INTRODUCTION Custom services to meet your research and development requirements Improvements in health, medicine and diagnostics over the past century can be largely
More informationChallenges and Opportunities of Monoclonal Antibody Manufacturing in China
BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More informationHow to Achieve a Flexible, High-Speed Filling Line
How to Achieve a Flexible, High-Speed Filling Line White Paper Hofäckerstraße 9 74564 Crailsheim Germany December 10, 2014 How to Achieve a Flexible, High Speed Filling Line Relying on dedicated filling
More informationBioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN 1538-8786
A Production of ISBioTech Summer 2010 Issue BioProcessing J O U R N A L Trends and Developments in BioProcess Technology Volume 9 Issue 1 ISSN 1538-8786 Trends & Developments in BioProcess Technology Novel
More informationIMPROVEMENT OF RECOMBINANT PROTEIN S COST OF GOODS & AFFORDABILITY
IMPROVEMENT OF RECOMBINANT PROTEIN S COST OF GOODS & AFFORDABILITY Li How Chen PhD Senior Director, revo Biologics Inc. USA Sami CHTOUROU PhD Senior Vice President Innovation & Scientific Affairs LFB Biotechnologies
More informationRisk-Based Change Management Using QbD Principles
Risk-Based Change Management Using QbD Principles Lynne Krummen, Ph.D. VP, Global Head, Technical Regulatory Biologics Genentech, a member of the Roche Group CMC Forum 2013 Tokyo, Japan Presentation Outline
More informationAnalyzing antibody sequence for recombinant antibody expression. Hangxing Yu, Ph.D Senior Scientist, GenScript May 20, 2015
Analyzing antibody sequence for recombinant antibody expression Hangxing Yu, Ph.D Senior Scientist, GenScript May 20, 2015 Presentation Outline 1 2 3 4 Antibody basics, structure and function Antibody
More informationImplementation of Advanced Chromatography techniques to Mitigate Purification Concerns in Bispecific Monoclonal Antibody Manufacturing
www.beroe- WHITEPAPER December 2012 inc.com Implementation of Advanced Chromatography techniques to Multi Column Solvent Gradient Purification or MCSGP chromatography process is a better solution to Bispecific
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationMultiple Products in a Monoclonal Antibody S88.01 Batch Plant
Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org
More informationHow single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs
WHITE PAPER 7004 How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs By John Boehm Business Unit Manager Colder Products Company Today s
More informationLifeTein in Industrial Production of Therapeutic Peptides. Phil Moore, PhD Director of Business Development LifeTein LLC, NJ, USA
LifeTein in Industrial Production of Therapeutic Peptides Phil Moore, PhD Director of Business Development LifeTein LLC, NJ, USA 1 Outline Market and Technology Trend LifeTein s Technology portfolio LifeTein
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationNUVISAN Pharma Services
NUVISAN Pharma Services CESI MS Now available! 1st CRO in Europe! At the highest levels of quality. LABORATORY SERVICES Equipment update STATE OF THE ART AT NUVISAN CESI MS Now available! 1st CRO in Europe!
More information2015 FOYA Award for facility integration Multipurpose Biologics and Vaccines Production Facility. IDT Biologika 2015 FOYA Award Facility Integration
2015 FOYA Award for facility integration Multipurpose Biologics and Vaccines Production Facility 1 Agenda ABOUT IDT BIOLOGIKA FACILITY HIGHLIGHTS AND INNOVATIVE FEATURES BUILDING CONCEPT AND PROJECT OVERVIEW
More informationAccelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development
Pharma&Biotech Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development James Rance PhD Head of Development Services Singapore Lonza Biologics
More informationBIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM
BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM FROM ORIGINATOR THROUGH COMPARABILITY TO MARKET STREAMLINE YOUR R&D, REGULATORY, ANALYTICAL, AND CLINICAL NEEDS WITH ONE PROVIDER The development pathway of
More informationGenScript Antibody Services
GenScript Antibody Services Scientific experts, innovative technologies, proven performance We specialize in custom antibody production to empower your research Custom Polyclonal Antibody Production Custom
More informationAntibody Services from GenScript
Services from GenScript www.genscript.com GenScript USA Inc. 860 Centennial Ave., Piscataway, NJ 08854 USA Toll-Free: 1-877-436-7274 Fax: 1-732-210-0262 1-732-885-5878 Academic Services Pharmaceutical
More informationNext-Generation Facilities for Monoclonal Antibody Production
Advancing Development & Manufacturing Facilities Next-Generation Facilities for Monoclonal Antibody Production Niels Guldager ELECTRONICALLY REPRINTED FROM JULY 2009 The biopharmaceutical industry faces
More informationPHARMACEUTICAL OUTSOURCING:
PHARMACEUTICAL OUTSOURCING: QUALITY MANAGEMENT AND PROJECT DELIVERY Trevor Deeks, Karen Ginsbury and Susan Schniepp Editors CONTENTS Preface 1 OVERVIEW OF OUTSOURCED OPERATIONS Susan Schniepp 2 LEGAL ASPECTS
More informationConsiderations Impacting the Make vs. Buy Decision
Considerations Impacting the Make vs. Buy Decision Thomas C. Ransohoff BioProcess Technology Consultants, Inc. INTRODUCTION AND BACKGROUND D ecisions related to manufacturing are among the most important
More informationA Risk Assessment of Pre-Licensure Manufacturing Changes
A Risk Assessment of Pre-Licensure Manufacturing Changes Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical Science FDA-CDER
More informationBio-manufacturing of antigens, antibodies and bioresearch materials
Bio-manufacturing of antigens, antibodies and bioresearch materials Foetal Bovine Serum (FBS) Human AB Serum Chick Embryo Extract (CEE) Custom polyclonal antibody production Custom monoclonal antibody
More informationAntibody Services. Best Guarantees in the Industry! Monoclonal Antibody Services. Polyclonal Antibody Services. Express Antibody TM Services
Antibody Services Best Guarantees in the Industry! Monoclonal Antibody Services Polyclonal Antibody Services Express Antibody TM Services Guaranteed Antibody Services Antibody Purification Services Your
More informationBiopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities
1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we
More informationFlexibility in a Biotech Manufacturing Facility: An Options Analysis for Monoclonal Antibody Production
Flexibility in a Biotech Manufacturing Facility: An Options Analysis for Monoclonal Antibody Production ESD.71 Engineering Systems Analysis for Design Professor Richard de Neufville December 8, 2011 EXECUTIVE
More informationTesting Services for Large Molecule Drug Development
Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,
More informationGo for the complete package.
Go for the complete package. Our services help you stand out in the market. Individual design options while leveraging the benefits of a device platform Flexible prototyping and devices for early studies
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More information